Clinical Trials e-Newsletter | June 2020

Clinical Trials e-Newsletter

Clinical Trials and COVID-19

Many of PHEN's partners have reactivated their clinical trials recruitment efforts after pausing during the COVID-19 pandemic.. . Read More

"Making Clinical Trials Work For You" Webinar Presentation

Keith Crawford, MD, PhD PHEN Director Clinical Trials and Patient Education Webinar Presentation June 18, 2020   kcrawford@prostatehealthed.org

Rubraca Approved by the FDA First PARP Inhibitor Drug For Prostate Cancer

RUBRACA (RUCAPARIB), has been approved by the FDA for treatment of men with prostate cancer. It is the first "PARP Inhibitor" therapy approved for prostate cancer patients. This class of drug is a type of targeted therapy that inhibits a tumor cell’s ability to repair itself, causing them to die. Patients with tumors that have evidence of genetic mutations are most likely to benefit from PARP Inhibitor treatment... Read More

More PARP Inhibitor Clinical Trials

These trials, like Rubraca, require prostate cancer patients to get genetic tests to determine if they have a genetic mutation.

KEYLYNK 010   View Patient Summary TALAPRO-1  View Patient Summary TALAPRO-2  View Patient Summary

MAGNITUDE  View Patient Summary GALAHAD  View Patient Summary TRITON-3  View Patient Summary

Multinational Study Suggests At Least 22% African American Men Should Participate in Clinical Trials

Find Your Trial (FYT) Tool

Find A Trial That Fits Your Needs Click on the link below that defines where you are on your prostate cancer journey and PHEN's "Find Your Trial (FYT) Tool" will present you with a listing of available clinical trials. Patients with Low and Intermediate Risk Prostate Cancer High Risk Prostate Cancer Patients Patients Treated with Prostatectomy or Radiation Patients with Recurrent Prostate Cancer Patients with Castration Resistant Prostate Cancer (CRPC)  Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients Understanding Castration Resistant Prostate Cancer Androgen deprivation (hormone) therapy, such as Lupron, works to reduce testosterone in the body to castration levels to prevent or slow the progression of prostate cancer. What is Castration resistant Prostate Cancer? Prostate cancer becomes Castration Resistant when the cancer progresses despite treatment with anti-androgen therapy. What is non-Metastatic Castration Resistant Prostate Cancer? Castration Resistant Prostate Cancer where no metastases have been detected.  What is Metastatic Castration Resistant Prostate Cancer?  Castration Resistant Prostate Cancer that has spread and metastasized to other parts of the body such as bones and other organs.

Bone Health

Understanding the Importance of Bone Health for Prostate Cancer Patients A very important, but often overlooked, aspect of treating Prostate Cancer in patients is the management of bone health. Read Here

What Are Clinical Trials?

Dictionary of Cancer Terms

Benefits of Clinical Trials

For more Clinical Trials Information visit: www.PHENtrials.org

PHEN Clinical Trial Rally Partners

STAY CONNECTED

‌ ‌